The potential of SGLT2 inhibition was indicated by a relative reduction of 26% in the combined risk of cardiovascular death or first hospitalization for heart failure and by a 25% decrease in recurrent hospitalizations for heart failure [97,98,99,100]. The gene discussed is SLC5A2; the disease is heart failure.